Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223203 · ClinicalTrials.gov registry record · Phase 3
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
A Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT07223203: Recruiting Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN, sponsored by Alnylam Pharmaceuticals.
NCT07223203 is a Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 125 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223203, a Phase 3 study of Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy and hATTR-PN, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Primary Outcome
The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome.
Conditions Studied
Interventions
- DRUG Nucresiran
- DRUG Vutrisiran
Study Locations (1)
Massachusetts
- Clinical Trial Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2031-06-12 |
| Phase | Phase 3 |
What NCT07223203 shows while recruiting
NCT07223203 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Nucresiran is the first listed.
NCT07223203 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07223203 about?
NCT07223203 is a clinical study titled "TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy". The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect t...
What is the current status of trial NCT07223203?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2026-01-16. Estimated completion is 2031-06-12.
What conditions does trial NCT07223203 study?
This clinical trial studies the following conditions: Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN.
What interventions are being tested in trial NCT07223203?
The interventions under investigation include: Nucresiran (DRUG), Vutrisiran (DRUG).
Who is sponsoring clinical trial NCT07223203?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223203 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07223203's enrollment target sits among peer trials
125 1606th of 2000 higher than 391 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI